SYBX Logo

Synlogic, Inc. (SYBX) 

NASDAQ
Market Cap
$16.78M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
734 of 776
Rank in Industry
404 of 433

Largest Insider Buys in Sector

SYBX Stock Price History Chart

SYBX Stock Performance

About Synlogic, Inc.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically …

Insider Activity of Synlogic, Inc.

Over the last 12 months, insiders at Synlogic, Inc. have bought $0 and sold $1,079 worth of Synlogic, Inc. stock.

On average, over the past 5 years, insiders at Synlogic, Inc. have bought $15,595 and sold $15,152 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 9,500 shares for transaction amount of $10,640 was made by JENSEN MICHAEL VANGSTED (Chief Financial Officer) on 2022‑05‑24.

List of Insider Buy and Sell Transactions, Synlogic, Inc.

2024-10-29SaleHead of Finance
79
0.0006%
$1.40$111-0.68%
2024-04-02SaleChief Operating Officer
372
0.0031%
$1.73$644-10.23%
2024-04-02SaleHead of Finance
188
0.0016%
$1.73$325-10.23%
2023-04-03SaleSee Remarks
19,042
0.0274%
$0.58$10,964+200.86%
2023-04-03SaleChief Operating Officer
6,438
0.0093%
$0.58$3,707+200.86%
2023-04-03SaleChief Financial Officer
2,553
0.0037%
$0.58$1,470+200.86%
2022-05-24PurchaseChief Financial Officer
9,500
0.0132%
$1.12$10,640-20.36%
2022-04-04SaleSee Remarks
8,894
0.0129%
$2.45$21,754-57.73%
2022-04-04SaleChief Operating Officer
2,650
0.0039%
$2.45$6,482-57.73%
2019-12-13Purchasedirector
7,500
0.0252%
$2.74$20,550-7.98%
2019-02-13SaleChief Scientific Officer
5,849
0.022%
$9.75$57,028-53.61%
2019-02-12SaleChief Scientific Officer
3,151
0.0127%
$9.75$30,722-50.05%
2018-10-18SaleChief Scientific Officer
3,000
0.0132%
$9.77$29,296-16.09%
2018-09-18SaleChief Scientific Officer
3,000
0.0119%
$13.05$39,163-38.59%
2018-09-05SaleChief Scientific Officer
3,000
0.0117%
$12.55$37,635-36.76%
2018-08-30SaleChief Scientific Officer
1,342
0.0052%
$9.76$13,092-19.08%
2018-08-29SaleChief Scientific Officer
1,658
0.0067%
$9.77$16,198-15.54%
2018-07-18SaleChief Scientific Officer
3,000
0.0118%
$11.01$33,022-25.32%
2018-06-20SaleChief Scientific Officer
2,054
0.0081%
$9.78$20,079-17.00%
2018-06-19SaleChief Scientific Officer
946
0.0039%
$9.75$9,224-13.81%

Insider Historical Profitability

<0.0001%
POWELL MICHAEL
2974811
25.4342%
$1.4410<0.0001%
Sofinnova Venture Partners VIII, L.P.10 percent owner
2974811
25.4342%
$1.4410<0.0001%
BARRIS PETER J10 percent owner
2971517
25.406%
$1.4410<0.0001%
BARRETT M JAMES10 percent owner
2971517
25.406%
$1.4410<0.0001%
MOTT DAVID M10 percent owner
2971517
25.406%
$1.4410<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Nea Management Company Llc$5.23M24.972.92M0%-$3.580.02
Fidelity Investments$412,074.001.97230,209-10.99%-$50,898.64<0.0001
The Vanguard Group$327,574.001.56183,002-2.88%-$9,721.50<0.0001
Renaissance Technologies$212,000.001.01118,435+116.8%+$114,211.68<0.0001
Geode Capital Management$85,207.000.4147,597+7.14%+$5,682.02<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.